292 related articles for article (PubMed ID: 24021375)
1. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
[TBL] [Abstract][Full Text] [Related]
2. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
[TBL] [Abstract][Full Text] [Related]
4. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib-induced neutrophilic panniculitis.
Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.
West ES; Williams VL; Morelli JG
Pediatr Dermatol; 2015; 32(1):153-4. PubMed ID: 24602192
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
9. Panniculitis in patients treated with BRAF inhibitors: a case series.
Choy B; Chou S; Anforth R; Fernández-Peñas P
Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511
[TBL] [Abstract][Full Text] [Related]
10. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
Chaminade A; Conte H; Jouary T; Fauconneau A; Darrigade AS; Beylot-Barry M; Pham-Ledard A
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
[No Abstract] [Full Text] [Related]
12. Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469793
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
14. RASopathic alopecia: hair changes associated with vemurafenib therapy.
Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
[No Abstract] [Full Text] [Related]
15. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
Kim GH; Levy A; Compoginis G
J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
19. Toxic epidermal necrolysis induced by vemurafenib.
Lapresta A; Dotor A; González-Herrada C
Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
[No Abstract] [Full Text] [Related]
20. Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
Grey A; Cooper A; McNeil C; O'Toole S; Thompson J; Grimison P
Intern Med J; 2014 Jun; 44(6):597-600. PubMed ID: 24946815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
